ÖZKAN, E. Et Al. 2023. PRe-treatment 68Ga-PSMA PET/CT parameters could predict response to 177Lu-PSMA tretament and overall survival in metastatic castration resistant prostate carcinoma patients treated with 177Lu-PSMA. Annuals Congress of the European Association of Nuclear Medicine .

ÖZKAN, E., DEMİR, B., ÖZTÜRK, M., ARAZ, M., SOYDAL, Ç., DURSUN, B., ... ÜRÜN, Y.(2023). PRe-treatment 68Ga-PSMA PET/CT parameters could predict response to 177Lu-PSMA tretament and overall survival in metastatic castration resistant prostate carcinoma patients treated with 177Lu-PSMA . Annuals Congress of the European Association of Nuclear Medicine

ÖZKAN, ELGİN Et Al. "PRe-treatment 68Ga-PSMA PET/CT parameters could predict response to 177Lu-PSMA tretament and overall survival in metastatic castration resistant prostate carcinoma patients treated with 177Lu-PSMA," Annuals Congress of the European Association of Nuclear Medicine, 2023

ÖZKAN, ELGİN Et Al. "PRe-treatment 68Ga-PSMA PET/CT parameters could predict response to 177Lu-PSMA tretament and overall survival in metastatic castration resistant prostate carcinoma patients treated with 177Lu-PSMA." Annuals Congress of the European Association of Nuclear Medicine , 2023

ÖZKAN, E. Et Al. (2023) . "PRe-treatment 68Ga-PSMA PET/CT parameters could predict response to 177Lu-PSMA tretament and overall survival in metastatic castration resistant prostate carcinoma patients treated with 177Lu-PSMA." Annuals Congress of the European Association of Nuclear Medicine .

@conferencepaper{conferencepaper, author={ELGİN ÖZKAN Et Al. }, title={PRe-treatment 68Ga-PSMA PET/CT parameters could predict response to 177Lu-PSMA tretament and overall survival in metastatic castration resistant prostate carcinoma patients treated with 177Lu-PSMA}, congress name={Annuals Congress of the European Association of Nuclear Medicine}, city={}, country={}, year={2023}}